Puma Biotechnology Inc (NASDAQ: PBYI)
$3.94
+0.2800 ( +7.65% ) 335.1K
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Market Data
Open
$3.94
Previous close
$3.66
Volume
335.1K
Market cap
$190.54M
Day range
$3.71 - $3.98
52 week range
$2.13 - $7.73
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 02, 2024 |
4 | Insider transactions | 1 | Jul 02, 2024 |
4 | Insider transactions | 1 | Jul 02, 2024 |
4 | Insider transactions | 1 | Jul 02, 2024 |
8-k | 8K-related | 15 | Jun 24, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |